Histamine glutarimide - EURRUS Biotech

Drug Profile

Histamine glutarimide - EURRUS Biotech

Alternative Names: XC-8

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer EURRUS BIOTECH; Pharmenterprises
  • Class Antiasthmatics; Antibronchitics; Biogenic amines; Peptides
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Respiratory tract infections
  • Phase II Asthma

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Russia (PO, Tablet)
  • 27 Sep 2017 Pharmaenterprises and EURRUS Biotech completes phase II trials in Asthma (Treatment-experienced) in Russia (NCT03450434)
  • 07 Sep 2017 Immunogenicity and adverse events data from preclinical studies in Asthma released by EURRUS Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top